Atlas Venture, the Cambridge, Ma.-based early-stage, biotech-focused venture firm, has for the first time raised an opportunity fund designed to help it support its most promising, maturing portfolio companies. The $250 million fund, announced by the firm this morning, is pretty well-timed as these things go. Though the public markets have bounced back a bit […]